Breaking News Headlines Today

News from go2.org

See all of go2.org’s headline news. Compare how the top news stories are covered by left-wing and right-wing news sources.

We’ve discovered 19 headlines written by go2.org during the past 3 months.

Ground News rates go2.org’s media bias as unknown. Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, All Sides, and Media Bias/Fact Check.

We’ve assigned a rating of Unknown factuality to go2.org. You can read more about how we’ve determined go2.org’s credibility and reliability as a news source here: https://ground.news/rating-system.

Information about go2.org

Where is go2.org located?go2.org's Website

Media Bias Ratings

Do you disagree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top go2.org News

Business · United States

FDA Approves Hernexeos as First Oral Therapy for NSCLC with HER2 Mutations

67% Left coverage: 12 sources

The FDA granted accelerated approved to zongertinib as the first oral treatment for adults with unresectable or metastatic HER2-mutant non-squamous non-small cell lung cancer, according to press release from Boehringer Ingelheim.See the Story

GO2 for Lung Cancer and the Addario Lung Cancer Medical Institute Honor Karen Kelly, MD with the 2025 Bonnie J. Addario Lectureship Award - GO2 for Lung Cancer

SAN CARLOS, CA – July 26, 2025 — GO2 for Lung Cancer (GO2) and the Addario Lung Cancer Medical Institute (ALCMI) are proud to announce that Karen Kelly, MD, chief executive officer of the International Association for the Study of Lung Cancer (IASLC), has been selected as the 2025 recipient of the Bonnie J. Addario Lectureship Award. The award recognizes Dr. Kelly’s exceptional leadership and longstanding commitment to advancing the field of lun…Maryland · Maryland Read Article

FDA Approves AstraZeneca And Daiichi Sankyo's Datroway For EGFR-Mutated Lung Cancer - AstraZeneca (NASDAQ:AZN)

75% Center coverage: 4 sources

FDA grants accelerated approval to AstraZeneca's Datroway for EGFR-mutant NSCLC after prior therapies, with a 45% response rate and a $45 million milestone due.Pharma · United States See the Story

A Mother and Son on a Mission: Rina’s Story - GO2 for Lung Cancer

Rina A. grew up on a corn farm in Nebraska and now lives in Debary, FL, with her soulmate and husband, John. She has worked at Stetson University for 20 years and is currently the presidential liaison for philanthropic and strategic partnerships for the university. Her son, Michey, grew up in Orlando, FL, and now resides in Washington, D.C., where he serves as a senior government affairs policy professional at Revvity, a leading life sciences an…Andalusia, Spain · Andalusia See the Story

Next-Generation TKI Approved for Advanced ROS1-Positive Lung Cancer

100% Center coverage: 2 sources

(MedPage Today) -- The FDA approved taletrectinib (Ibtrozi) -- a next-generation oral ROS1 tyrosine kinase inhibitor (TKI) -- for the treatment of adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC)...Pharma · United States See the Story

News from go2.org